Brief: Lepu Biopharma Expects FY Net Profit Attributable
10/03/2026 22:36
March 11 (Reuters) - Lepu Biopharma Co Ltd 2157.HK: EXPECTS FY NET PROFIT ATTRIBUTABLE OF AT LEAST RMB200 MILLION EXPECTED RESULT DUE TO REVENUE INCREASE FROM PUYOUHENG AND MEIYOUHENG AFTER NMPA APPROVAL IN OCTOBER 2025, OTHERS IN FY Further company coverage: 2157.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lepu Biopharma
See all newsChina's Lepu Biopharma H1 revenue rises 12.1% on higher drug sales
Hong Kong-listed Keymed Biosciences' gastric cancer drug meets late-stage trial goals
Brief: Lepu Biopharma Reports Positive Top-Line Results From Global Phase III Trial Of CMG901 (AZD0901)
Lepu Biopharma set to jump most in 7 months on FY profit forecast
Brief: Lepu Biopharma Expects FY Net Profit Attributable